BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
3.570
+0.090 (2.59%)
Feb 5, 2025, 10:54 AM EST - Market open
BioLineRx Revenue
BioLineRx had revenue of $4.94M in the quarter ending September 30, 2024. This brings the company's revenue in the last twelve months to $21.99M. In the year 2023, BioLineRx had annual revenue of $4.80M.
Revenue (ttm)
$21.99M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
$278,367
Employees
79
Market Cap
13.16M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
Novartis AG | 51.72B |
AstraZeneca | 51.21B |
Thermo Fisher Scientific | 42.88B |
Abbott Laboratories | 41.95B |
BLRX News
- 15 days ago - BioLineRx Issues Letter to Shareholders - PRNewsWire
- 19 days ago - BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares - PRNewsWire
- 4 weeks ago - Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet - Benzinga
- 4 weeks ago - BioLineRx Announces $10 Million Registered Direct Offering - PRNewsWire
- 2 months ago - BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value - PRNewsWire
- 2 months ago - BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd. - PRNewsWire
- 2 months ago - BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 - PRNewsWire